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Objectives. To explore the lived experience of youth, caregivers, and prescribers with antipsychotic medications. Design. We
conducted a qualitative interpretive phenomenology study. Youth aged 11 to 25 with recent experience taking antipsychotics,
the caregivers of youth taking antipsychotics, and the prescribers of antipsychotics were recruited. Subjects. Eighteen youth, 10
caregivers (parents), and 11 prescribers participated. Results. Eleven of 18 youth, six of ten parents, and all prescribers discussed
antipsychotic-related weight gain. Participants were attuned to the numeric weight changes usuallymeasured in pounds. Significant
discussions occurred around weight changes in the context of body image, adherence and persistence, managing weight increases,
and metabolic effects.These concepts were often inextricably linked but maintained the significance as separate issues. Participants
discussed tradeoffs regarding the perceived benefits and risks of weight gain, often with uncertainty and inadequate information
regarding the short- and long-term consequences. Conclusion. Antipsychotic-related weight gain in youth influences body image
and weight management strategies and impacts treatment courses with respect to adherence and persistence. In our study, the
experience of monitoring for weight and metabolic changes was primarily reactive in nature. Participants expressed ambiguity
regarding the short- and long-term consequences of weight and metabolic changes.
1. Introduction
Second generation antipsychotic prescribing to young people
under 25 years of age is increasing internationally [1–12]. The
rise in prescription trends has generated controversy given
available pediatric evidence for second generation antipsy-
chotic effectiveness and safety data and the unknown long-
term consequences with intermittent or continuous exposure
[13–16]. Antipsychotic-related weight gain and changes in the
metabolic profile (e.g., glucose and lipid homeostasis) that
occur following, or in concert with, weight gain are frequently
discussed as significant treatment-related issues. The explicit
mechanisms of antipsychotic-relatedweight gain are not fully
understood [17–24] nor are the best management approaches
(e.g., lifestyle, pharmacologic), but research in these areas
continues [17, 25–33].
Predictive or risk factors for antipsychotic-related weight
gain are also unknown but some inferences can bemade from
available syntheses of the literature. These factors include
lower pretreatment body mass index (BMI), triglyceride
levels, more negative symptoms, polypharmacy, concomitant
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antidepressants, and younger age [34, 35]. Predisposing
factors are similar for pediatrics and antipsychotic-na¨ıve
patients, and younger age groups appear to be at highest risk
[36, 37].Weight gainmay also bemore dramaticwith younger
patients compared to adults [36].
Given the local and international trends in utilization and
controversies regarding effectiveness and safety of antipsy-
chotics, we explored the lived experience of youth taking
antipsychotics, their caregivers, and prescribers through a
qualitative study using an interpretive phenomenological
approach. This paper focuses on the experience of weight
gain for youth taking antipsychotics, their caregivers, and the
prescribers.
2. Methods
To understand the experience of antipsychotic use, we
used interpretive phenomenology. Phenomenology studies
the person in the situation, rather than in isolation [38].
We followed a staged approach modeled after Diekelmann
et al. [39]. In stage one, all transcripts were read by AM
and DG as a whole to gain a complete picture or overall
understanding of the data considering weight gain. In stage
two, we summarized sections of the transcripts and identified
categories within weight gain. We met weekly for a month
to discuss our interpretations of the categories and provided
text quotes to demonstrate support. We worked to achieve
consensus in the categories. In stage three, we continued
with independent analysis of transcripts and compared inter-
pretations of the categories with supporting text. In stage
four, we sought to examine relational themes.Throughout the
process we engaged in reflexivity through journaling. Among
other strategies, our analysis process facilitated achieving
credibility and dependability. We used several approaches
for confirmability and transferability. Transferability may be
limited to an extent as the study occurred within a Canadian
province with a predominantly publically financed system
(70% public, 30% private).
3. Sample and Recruitment Procedures
We recruited low income youth, defined as youth receiving
government income assistance, aged 11 to 25 years, who
were prescribed antipsychotics within the last two years.
We also recruited their caregivers/support people. General
practitioners and psychiatrists who prescribed antipsychotics
to youth in the last six months and licensed to practice in
Nova Scotia, a Canadian province, were eligible and were
informed of the study for physician recruitment purposes
and also to facilitate youth and caregiver recruitment. We
advertised broadly in public places and on the Internet. All
participants were offered the choice of a one time interview
or focus group, and each participant was paid a one-time
honorarium.
4. Data Collection
Separate interview guides (available upon request) with main
and probing questions were developed for each group of
participants. Youth, caregiver, and physician interviews and
one physician focus group were conducted between January
of 2010 and August of 2010. All interactions with participants
were recorded and transcribed except one face-to-face inter-
view (one youth refused to be recorded). All audio recordings
were transcribed, and, during cleaning of transcripts by the
interviewer, field notes and jottings were used to insert
comments and reflections when appropriate. Responsive
interviewing techniques were used with an iterative process
of data analysis occurring during data collection [40]. Once
cleaned, transcripts were stored and organized using Atlas.ti
6.2.
4.1. Ethical Approvals. Ethics approval was obtained from
the research ethics boards (REB) of Capital District Health
Authority and the IWK Health Centre given that our popu-
lation spanned young people and adults. Both of these REBs
have reciprocal ethical agreements with Dalhousie University
REB.
4.2. Findings. The theme of weight gain emerged from an
analysis of approximately 13 hours of audio from 18 youths
who ranged in age from 13 to 26. Table 1 shows the range
of medications and diagnoses as described by participants.
The two 26-year olds were included in the analysis as their
most recent antipsychotic exposures were in their 25th year
of life. One youth and caregiver pair were related (i.e., mother
and son) in our study, and they were interviewed separately.
We collected 11 audio hours from 10 female caregivers, who
will herein be referred to as “parents” given all caregivers
described themselves as a “parent” and 7 audio hours from
11 prescribers (𝑛 = 5 prescribers in a focus group and 𝑛 = 6
prescriber individual interviews).
Eleven of 18 youth, six of ten parents, and all prescribers
discussed antipsychotic-related weight gain. Participants
were highly attuned to the number in pounds as a metric for
weight changes. Within the theme of weight gain, we further
categorized and coded the data with body image, adherence
and persistence,managingweight gain, andmetabolic effects.
Within the experiences of participants, these concepts were
often inextricably linked, but each maintained significance as
a separate concept.
4.3. Body Image. Changes in body weight affected body
image and the potential to experience stigma related toweight
gain. Youth were not only coping with their own emotions
with weight changes but also managing the responses of
others to their physical appearance. Parents and prescribers
similarly discussed the concept of body image, but the
concerns more shifted towards long-term implications of
weight gain from a safety lens or adherence to medications.
Prescribers’ perceptions of the youth consciousness with
weight changes were an underlying consideration in the
prescriber choice of antipsychotic and anticipated adherence
patterns in youth.
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Table 1: Youth participant demographics and self-reported medications and diagnoses.
Youth Gender Age Medication(s) named in participant experiences Self-reported conditions
(1) Youth 1 Female 19 Quetiapine, Strattera, Adderall Bipolar, depressed, mood disorder,anxiety, panic attacks
(2) Antidepressant interview
(3) Youth 2 Female 26 Olanzapine, lorazepam, risperidone, citalopram,trazodone
Psychosis, psychosis not otherwise
specified, sleep disorder
(4) Youth 3 Male 25 Risperidone, olanzapine, ziprasidone, citalopram Psychosis
(5) Youth 4 Male 24 Paxil, lithium, “a lot of different antipsychotics”
Depression, paranoid, bipolar
schizophrenia, bipolar,
schizo-affective, schizophrenia with
bipolar
(6) Youth 5 Female 18 Quetiapine, Cipralex, clonazepam OCD∗, anxiety
(7) Youth 6 Female 21 Quetiapine, lorazepam, Risperdal, Celexa, Effexor Schizophrenic, bipolar
(8) Youth 7 Male 24 Risperidone Psychosis
(9) Youth 8 Male 17 Quetiapine Paranoia
(10) Antidepressant interview
(11) Youth 9 Male 26 Divalproex, olanzapine, clonazepam, Dilaudid ADHD†, “bipolar schizophrenic”
(12) Youth 10 Female 23 Cipralex, Wellbutrin, clonazepam, risperidone Drug-induced psychosis, Paranoidschizophrenia, ADHD†, anxiety
(13) Youth 11 Female 25 Lithium, olanzapine, citalopram, Ciprolex,citalopram, Wellbutrin, zopiclone Anxiety, depression, bipolar, manic
(14) Youth 12 Female 21 Quetiapine, Zoloft, risperidone, Prozac, Paxil,lorazepam, clonazepam, diazepam, lorazepam Borderline personality disorder
(15) Youth 13 Female 22 Lithium, risperidone, ziprasidone, Cipralex,Epival Bipolar, psychosis
(16) Youth 14 Male 20 Risperidone, Dexedrine, Ritalin, Wellbutrin ADHD
†, ADD‡, seizure disorder,
autism
(17) Youth 15 Male 13 Biphentin, risperidone ADHD
†, anger problem, violent
behaviour
∗OCD: Obsessive compulsive disorder.
†ADHD: attention deficit hyperactivity disorder.
‡ADD: attention deficit disorder.
Youth 9:
“I don’t like that I have a belly. People are like,
‘Oh, you got chubby in the face.’ And I’m like, ‘It’s
because I’m taking my medication, bastard. Shut
the f%$# up!’.”
Youth 11:
“. . . I’ve gained at least 15 pounds. And
probably. . . I heard that usually there’s a 6
month cap on it. So I’m in the clear, I guess. But
I’m completely unhappy with my body.”
4.4. Managing Weight Gain. Participants in our study dis-
cussed strategies that were used in mitigating weight gain or
managing potential or existing weight gain through various
choices. These included consideration of the initial choice of
antipsychotic in terms of its potential to cause weight gain,
switching of antipsychotics, lifestyle interventions (e.g., diet,
exercise), pharmacological treatments, and nonadherence or
eventual antipsychotic discontinuation.
For youth, there was a frustration expressed when results
of their efforts to minimize weight gain were not what they
expected. Youth employed lifestyle strategies such as diet and
exercise or talked about planning to initiate these strategies.
Medication switches were discussed although these were
initiated by prescribers. Discontinuation initiated by youth
themselves was also used as an approach to stopping weight
gain.
One prescriber in the focus group was the only pre-
scriber to discuss nonswitch pharmacologic options such as
metformin to manage antipsychotic induced weight gain,
and other members of the group appeared unaware of this
option based on the ensuing discussion. For initial antipsy-
chotic choice, several prescribers discussed their previous
experiences with patients who had gained weight and also
their own values as being influential in how they made their
antipsychotic choices.
Parents discussed youth engaging in behaviours to man-
age weight including exercising and dieting and also stopping
medications. It was also evident from several parents that they
made distinctions among antipsychotics, including “newer”
versus “older” agents, about which were better or worse
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for causing weight gain, and revealing preferences for agent
choice for their youth.
Youth 7:
“. . . And I was exercising, eating the same way. I
find taking weight off is impossible. Weight gain,
weight gain, weight gain. Big time on the weight
gain on the pill.”
Youth 13:
“Well, I had a lot of weight gain on the Risperdal.
Interviewer: And is this one supposed to be better?
Youth 13: Yes, it’s supposed to be better and it has
been because I’ve actually lost weight on it since. . .
. . . Interviewer: Can you put a number on what
you think you’ve gained? Youth 13: Overall, it was
like 100 pounds.”
Parent 7:
“. . . The Seroquel is not as bad as the Risperdal.
. . . Yes. But the Seroquel has a weight gain thing
too but it’s not as bad for her anyway.”
Prescriber 4:
“And a situation where I have 2 parents who are
[profession] [and] a child with autism. I started
the child on the medication. The child started to
gainweight.Theywere so desperate to keep him on
medication because it changed his life, it changed
their life. They did everything possible in the
way of diet management, exercise management.
Just everything possible to make sure that they
minimized any metabolic effects.”
Prescriber 5:
“. . . If somebody told me, ‘Take this drug. It will
make you feel better but you will gain 30 pounds,’
I’d say, ‘no thanks’.”
4.5. Adherence and Persistence. Adherence is described as
the extent that patients follow instructions provided for
treatments [41] including conforming to dosing, frequency,
and timing of medications [42]. Persistence is defined as
the length of time that a therapy is taken from initiation to
discontinuation [42]. Medication adherence and persistence
are considered important components in managing symp-
toms of mental illness. Participants in our study discussed
adherence, nonadherence, and choicesmadewith persistence
to medication directly in the context of weight gain. It seems
that youthwhowere committed to adhering to, and persisting
with, their antipsychotics had realized or perceived a benefit
from treatment or understood it to be important. Youth 7
discussed exercising in response to gaining “40 pounds in
ninemonths” after he “agreed to take” hismedication and also
stating, “I’ve got to stay on thismedication and keep taking it”.
For one youth, she discussed discontinuing her antipsychotic
due to sedation and weight gain and that this decision
irreparably altered the patient-prescriber relationship.
Prescribers similarly discussed how weight gain would
promote nonadherence, and this mainly centred on the belief
that youth would be concernedwith body image.Weight gain
was generally seen as a barrier to adherence and a reason
for nonadherence and lack of persistence. One prescriber’s
experience was that youth often withheld information about
whether they persist with therapies. It also became evident
that, for some prescribers, they toowere challenged regarding
adherence and persistence with intended treatment courses
for their patient in light of weight gain. One prescriber shared
information around ambivalence when weight gain occurs in
the face of benefits.
Youth 2:
“Like January/February 2008 when I stopped
taking this medication, I went to him and I was
like, ‘Look, I don’t know why I’m taking this. It’s
a small dose but I’m tired all the time. I’m gaining
weight.’ And I’m like, ‘I’ve actually already stopped
taking it.’ And he’s like, ‘Well, if you’re not going
to take the medication I prescribed you, there’s
nothing more I can do for you. I can have your
files transferred to a different psychiatrist,’ which
is closer to where I live so I wouldn’t have to go to
[city] every time.”
Parent 8:
“. . . Then she started to gain some weight with
the Invega. And my daughter is very petite and
very, very conscious of her appearance and things
like that. . . . And gaining weight just wasn’t in the
cards. And she was really quite upset by that. . . .
The barriers really are around the weight gain and
then they don’t want to stay on it.”
Focus Group
Prescriber 1:
“ So even though they may not be getting diabetic,
the fact that they’ve gained 25 pounds on one of
the antipsychotics, they may stop taking it. So that
will impact. And they don’t tell you.”
Prescriber 4:
“. . . Antipsychotic medications to some extent I
have a little more concern about. And yet parents
are a little less aware of that, unless they are well
informed parents. Or until the child has been on
the medication for 3 months and they start to see
the child is gaining a bit more weight than they
need. So we have to work to help them appreciate
that this is important. But then we run into a
different kind of ambivalence. The child might be
functioning really well but now they are uncertain
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what to do about the weight gain, and they don’t
want to lose the well functioning. They feel as
though they’ve got a child in their home for the
first time. So it’s a difficult situation. It’s a difficult
situation for us too.”
4.6. Metabolic Side Effects. There was a significant discussion
of “metabolic side effects”, which created decisional conflicts
for participants. Parents discussed concerns of the long-term
consequences based on current weight or weight gain and
married this information with family histories of conditions
such as diabetes. One parent also discussed a concern
regarding a lack of monitoring regarding cholesterol. One
prescriber discussed heart disease and cholesterol whereas
others that discussed metabolic side effects in the context of
weight gain focused on diabetes and glucose.
Participants such as Youth 7 were concerned about
diabetes in light of existing lab values, but his experience
indicates he may not fully understand the possible risk or
potential likelihood of having the “list” of side effects.
Prescribers expressed concern regarding the side effects,
and one pleaded for judicious and rational use because
of limited long-term pharmacovigilance data. Prescriber 3
through encouraging the rational use of the medications also
shed light on wider systems issues. Although the medications
may be viewed as a “quick fix” for some in a cost-constrained
system, the potential long-term implications would not be
offset by immediate gratification. They also expressed con-
cern regarding adequacy of knowledge translation efforts
regarding the use of the medications.
Youth 7:
“The only other side effect I’m worrying about
actually with Risperdal. . . Well, one other side
effect is it can cause permanent diabetes. And my
blood sugar levels are a little bit high since I’ve been
taking the pill. And the other one is the inability to
conceive children.That’s also a possibility. And I’m
worried about that one. But I mean I get this list
of side effects, and I’m like, ‘Ah, what am I going
to get?’.”
Parent 9:
“ So I had major, major concerns because he put
on 70 pounds. . . . I am diabetic. And weight gain
is a major factor.”
Parent 5:
“Yes, I do have a family doctor but she. . . I haven’t
talked to her. Because one of the things I noticed
actually . . . I don’t think [psychiatrist’s name] had
mentioned it, or I didn’t actually pick it up, was
[son’s name] should probably actually have blood
work done so he has a base to go by. Because if
there’s any problems with cholesterol or anything
like that, he should kind of be watched. My doctor
is not the greatest. You can get in to her right
quick and she can give you a pad and then out
you go. But he hasn’t actually talked to her about
anything.”
Focus Group Discussion
Prescriber 1:
“I am seeing younger people like in the early 20s,
even in late teens, where if they have a family
history of diabetes as well, it’s really important to
get baseline blood work because it can happen.”
Interview, Prescriber 2:
“I tend to stay away from olanzapine because
I’ve had experience and . . . Well, I tend to use
quetiapine. That is such a crap shoot. And I don’t
know . . .This is more like the art or the cookery,
the recipe of medicine, but I’ve had experience
with clients becoming diabetic on olanzapine.”
Prescriber 3:
“. . . And not just a bit of change in your blood
sugar but diabetes, and changes in your choles-
terol, and setting people up for heart disease later
on. . . . . . . I just don’t know how widespread the
caution is yet. . . . Like people are like for the last
5 or 6 years have been like ‘okay, everybody, these
drugs are scary’. Like, let’s think. For some people,
they need them, but let’s be responsible. Let’s think
about who needs them, who doesn’t. Let’s think
about how long they need them. Let’s think about
how we monitor when they are on it to make
sure we don’t cause them life-long problems. . . But
I don’t know how well that knowledge has been
transmitted across the board in terms of people
prescribing. And I think there are serious pressures
because of resource issues, not just in [location]
but everywhere in mental health, that it’s easier
to. . . that drugs are more accessible in general, . . .
cost being a factor. But it’s easier to get a drug than
to get therapies in general.”
5. Discussion
Our qualitative study in the Canadian context is unique in
that it gives insights into the lived experiences of three groups
(youth, parents, and prescribers) with antipsychotic-related
weight gain and related implications in the broader context
of the lived experience of antipsychotics.
To our knowledge, this is the first study of this kind in
Canada. The experiences of youth, parents, and prescribers
were largely negative regarding weight gain and impacted
body image and adherence and persistence withmedications.
Managing weight gain was a complex phenomenon, and var-
ious strategies were reported by participants. An overarching
fear and concern related to metabolic side effects was evident
in our data.
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The rising prevalence of obesity in Canadian children and
adolescents has become a public health concern [43, 44]. Ball
and McCargar [43] conducted a review of prevalence and
risk factor literature from studies in children and adolescents.
The etiology of increasingly overweight and obese children
and adolescents is thought to be multifactorial including
such factors related to lifestyle (e.g., limited physical activ-
ity, rising physical inactivity), eating behaviours and nutri-
tion, and higher height and weight subsequently leading
to higher BMIs with earlier maturation [43]. Medications,
including psychotropics, can also cause weight gain in chil-
dren and adolescents [45, 46]. Meta-analysis data ranking
antipsychotic-related weight gain are available for adults [47],
and mean weight changes with antipsychotics versus placebo
in children up to 18 years of age show higher increases with
olanzapine at 3.47 kg (95% CI 2.94, 3.99), risperidone with
1.72 kg (95%CI 1.17, 2.26), quetiapinewith 1.41 kg (95%CI 1.10,
1.81), and aripiprazole at 0.85 kg (95% CI 0.58, 1.13) [15]. The
experience of weight gain with antipsychotics as discussed
in our study from youth, parent, and prescriber perspectives
focused heavily on numeric values in pounds of weight
with wide ranges of weight gain described. An inherent
limitation in our study is the inability to determine if the
changes self-reported by youth and parents were abnormal.
We did not explicitly link weight gain with diet, physical
activity, other concomitantmedications, or family histories of
cardiometabolic conditions. Based on the experience of some
youth and parents reportingweight gains of 70 to 100 pounds,
we can infer that this would be considered abnormal and its
consequences in some cases would be considered significant.
There was a general concern from both the prescribers and
parents that the weight gain they observed, regardless of the
quantity, was a negative consequence of antipsychotics for
youth.
Several anthropometric measures of body adiposity (e.g.,
weight, BMI, height to weight ratio, waist circumference, etc.)
are available, and a standardization regarding what metrics
should be used remains to be established [48].The association
of these metrics with cardiometabolic disease in adults is
varied, and more research is required with the application of
these metrics to long-term outcomes in children [34, 36, 43,
49–51]. The current Canadian guidelines published in 2011
on the monitoring of weight-related measures in children
and adolescents taking antipsychotics recommend BMI and
waist circumference measurements [52]. In our study, weight
was reported as a change (i.e., increase) and in pounds. BMI
and other measurements were not discussed. The Canadian
guidelines were not published at the time of our interviews
in 2010. The guidelines provide a good basis for clinicians
to engage in monitoring practices; however, it is difficult in
the context of individual patients to determine how much
weight gain can be caused by individual psychotropics, the
velocity at which it occurs, whether it plateaus, who is most
at risk, how to manage it, and what significance is produced
by the outcome given that the research in this area is limited
in high quality studies of ample quantity [47, 53]. To date,
studies that have examined monitoring practices show that
of all parameters suggested for monitoring, weight measures
are the most commonly performed [54].
A major conundrum that is apparent in the literature on
the topic of antipsychotic-related weight gain in youth, or as
identified in our study as “ambivalence,” emerged from our
data andwas aptly described by a prescriber discussingweight
gain occurring in concert with much anticipated and hoped
for benefits of therapy. The issue of what to do in response
to weight gain is especially complex when perceived positive
impacts occur. Weight gain is really one of several surrogate
markers of interest in relation to cardiometabolic diseases.
The potential association with chronic disease (e.g., cardio-
vascular and endocrine) development and related morbidity
and mortality is of great importance given the significant
strain on population health and economic and social welfare
[55].The issue ofweight gain is complicated in clinical scenar-
ios by the fact thatmore than onemedication in a regimen can
be the cause (e.g., lithium and olanzapine used in managing
bipolar disorder) or even mitigating it (e.g., stimulants).
Weight changes are also set against a backdrop of physical
changes occurring at developmental stages and changes in
weight that may have occurred due to illness. Further, more
data is needed to provide clarity regarding weight gain and
cardiometabolic risks in youth taking these medications [36].
Because of these simultaneously moving targets and need
for better data, making decisions regarding the appropriate
course of action can be extremely complicated for youth,
families, and prescribers. How these factors are prioritized
in decision making within these three groups is not well
known. In our study, the concerns for metabolic side effects
and weight gain were apparent and influential on behaviours.
Prescribers discussed their own personal values and tacit
experience with treating patients and decisional dilemmas
around choice of agents with one describing it as “such a crap
shoot”. Past experiences with patients developing diabetes
steered one prescriber away from using the medications.
Parents also described their knowledge of the side effects
from what they observed and their concerns based on family
histories of metabolic conditions (e.g., diabetes). Although
the concern by parents was expressed, there was little reso-
lution in their conflicted feelings as it appears that the youth
and prescriber ultimately would be making decisions about
weight management.
Interestingly, the prescribers in our study tended to
be focused on glucose related complications more so than
cholesterol with only one prescriber discussing “heart dis-
ease” and cholesterol. The parent and youth experience
of prescriber based monitoring appeared to be variable in
quantity and quality. Rates of guideline concordant moni-
toring of antipsychotic-related cardiometabolic side effects
are often poor [54]. The approach to managing and mon-
itoring antipsychotic-related weight gain and potential car-
diometabolic effects appears mainly reactive without fore-
thought of a larger management plan for mitigating the
effects.
In addition to potential physical health concerns created
by obesity, negative psychosocial consequences can result
from being overweight and obese [43]. Youth in our study
described impacts on body image. In adults, psychotropic
related weight gain has been shown to impair quality of
life proportionally with weight gain and increased feeling of
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hopelessness and decreased self-worth [56]. Further explica-
tion of the complex relationships with antipsychotic-related
weight gain in youth and its effects on quality of life, self
image, and its impact on adherence in younger people is
warranted [57].
This qualitative study demonstrates that antipsychotic-
related weight gain is associated with significant physical, and
mental consequences and there is a shared concern regarding
these sequelae among youth, parents, and prescribers. More
research is needed regarding the short- and long-term impli-
cations of weight gain and cardiometabolic effects and how
the risks and benefits of treatment are managed by patients
and prescribers in therapeutic decision making.
List of Brand Name Medications
(Alphabetical) Discussed by Participants and
Their Respective Generic Names
Adderall: Dextroamphetamine and
levoamphetamine mixed salts
Biphentin: Methylphenidate
Cipralex: Escitalopram
Dexedrine: Dextroamphetamine
Dilaudid: Hydromorphone
Epival: Divalproex sodium
Invega: Paliperidone
Paxil: Paroxetine
Prozac: Fluoxetine
Risperdal: Risperidone
Ritalin: Methylphenidate
Seroquel: Quetiapine
Strattera: Atomoxetine
Wellbutrin: Bupropion
Zoloft: Sertraline.
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